Title:
NOVEL ANTIBODY TO CD55 AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/154472
Kind Code:
A1
Abstract:
The present invention relates to an antibody specifically binding to CD55, or an antigen-binding fragment thereof; and a composition for prophylactic treatment and/or diagnosis of cancer comprising same. The antibody of the present invention may be used as an effective therapeutic composition for various CD55-mediated diseases by showing high binding to and inhibitory abilities against a CD55 protein that promotes tumor growth by suppressing the complement immune mechanism. In addition, the antibody of the present invention may be utilized as an effective therapeutic adjuvant that fundamentally removes drug resistance and significantly improves therapeutic responsiveness in various diseases in which resistance to therapeutic agents with complement dependent cytotoxicity (CDC) as a mechanism of action is induced due to overexpression of CD55.
Inventors:
LEE JI CHUL (KR)
PARK HYE IN (KR)
MIN SUNG-WON (KR)
KWON HYEONG SUN (KR)
JUNG SANG TAEK (KR)
LIM JAE CHEONG (KR)
DOH SO HEE (KR)
CHO EUN HA (KR)
LEE SO-YOUNG (KR)
JUNG SUNG HEE (KR)
PARK HYE IN (KR)
MIN SUNG-WON (KR)
KWON HYEONG SUN (KR)
JUNG SANG TAEK (KR)
LIM JAE CHEONG (KR)
DOH SO HEE (KR)
CHO EUN HA (KR)
LEE SO-YOUNG (KR)
JUNG SUNG HEE (KR)
Application Number:
PCT/KR2022/000551
Publication Date:
July 21, 2022
Filing Date:
January 12, 2022
Export Citation:
Assignee:
SG MEDICAL INC (KR)
UNIV KOREA RES & BUS FOUND (KR)
KOREA ATOMIC ENERGY RES (KR)
UNIV KOREA RES & BUS FOUND (KR)
KOREA ATOMIC ENERGY RES (KR)
International Classes:
C07K16/28; A61K39/00; A61P35/00; G01N33/563; G01N33/574
Domestic Patent References:
| WO2006117782A2 | 2006-11-09 | |||
| WO1988010649A1 | ||||
| WO1988106630A1 | ||||
| WO1988007085A1 | 1988-09-22 | |||
| WO1988007086A1 | 1988-09-22 | |||
| WO1988009344A1 | 1988-12-01 |
Foreign References:
| KR101800774B1 | 2017-11-24 | |||
| KR20180040842A | 2018-04-23 | |||
| KR101800774B1 | 2017-11-24 | |||
| US5731168A | 1998-03-24 | |||
| US7695936B2 | 2010-04-13 | |||
| KR20160132333A | 2016-11-17 | |||
| US20100056386A1 | 2010-03-04 | |||
| US20140206849A1 | 2014-07-24 |
Other References:
DATABASE PROTEIN 17 September 2019 (2019-09-17), ANONYMOUS : "IGL c2238_light_IGLV3-1_IGLJ2, partial [Homo sapiens]", XP055950828, retrieved from NCBI Database accession no. QEP12299
DATABASE PROTEIN 1 December 2020 (2020-12-01), ANONYMOUS : "IGH c739_heavy_IGHV3-23_IGHD4-17_IGHJ4, partial [Homo sapiens]", XP055950826, retrieved from NCBI Database accession no. QEP15014
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
NEEDLEMANWUNSCH, J. MOL. BIO., vol. 48, 1970, pages 443
PEARSONLIPMAN, METHODS IN MOL. BIOL., vol. 24, 1988, pages 307 - 31
HIGGINSSHARP, GENE, vol. 73, 1988, pages 237 - 44
HIGGINSSHARP, CABIOS, vol. 5, 1989, pages 151 - 3
CORPET ET AL., NUC. ACIDS RES., vol. 16, 1988, pages 10881 - 90
HUANG ET AL., COMP. APPL. BIOSCI., vol. 8, 1992, pages 155 - 65
PEARSON ET AL., METH. MOL. BIOL., vol. 24, 1994, pages 307 - 31
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584
RIDGWAY ET AL., PROT ENG, vol. 9, 1996, pages 617 - 621
CARTER, J IMMUNOL METH, vol. 248, 2001, pages 7 - 15
GOLAY ET AL., BLOOD, vol. 95, no. 12, 2000, pages 3900 - 8
MACOR ET AL., LEUKEMIA, vol. 29, no. 2, 2014, pages 406 - 14
MOORE ET AL.: "A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats", METHODS, vol. 154, pages 38 - 50, XP055625796, DOI: 10.1016/j.ymeth.2018.10.006
GIESE ET AL., BIOTECHNOL PROG, vol. 34, no. 2, pages 397 - 404
DATABASE PROTEIN 1 December 2020 (2020-12-01), ANONYMOUS : "IGH c739_heavy_IGHV3-23_IGHD4-17_IGHJ4, partial [Homo sapiens]", XP055950826, retrieved from NCBI Database accession no. QEP15014
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
NEEDLEMANWUNSCH, J. MOL. BIO., vol. 48, 1970, pages 443
PEARSONLIPMAN, METHODS IN MOL. BIOL., vol. 24, 1988, pages 307 - 31
HIGGINSSHARP, GENE, vol. 73, 1988, pages 237 - 44
HIGGINSSHARP, CABIOS, vol. 5, 1989, pages 151 - 3
CORPET ET AL., NUC. ACIDS RES., vol. 16, 1988, pages 10881 - 90
HUANG ET AL., COMP. APPL. BIOSCI., vol. 8, 1992, pages 155 - 65
PEARSON ET AL., METH. MOL. BIOL., vol. 24, 1994, pages 307 - 31
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584
RIDGWAY ET AL., PROT ENG, vol. 9, 1996, pages 617 - 621
CARTER, J IMMUNOL METH, vol. 248, 2001, pages 7 - 15
GOLAY ET AL., BLOOD, vol. 95, no. 12, 2000, pages 3900 - 8
MACOR ET AL., LEUKEMIA, vol. 29, no. 2, 2014, pages 406 - 14
MOORE ET AL.: "A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats", METHODS, vol. 154, pages 38 - 50, XP055625796, DOI: 10.1016/j.ymeth.2018.10.006
GIESE ET AL., BIOTECHNOL PROG, vol. 34, no. 2, pages 397 - 404
Attorney, Agent or Firm:
CHUNG HYUN PATENT & LAW FIRM (KR)
Download PDF: